Literature DB >> 9299944

Detecting familial defective apolipoprotein B-100: three molecular scanning methods compared.

B G Henderson1, P R Wenham, J P Ashby, G Blundell.   

Abstract

Familial defective apolipoprotein (apo) B-100 (FDB), a condition that may give rise to hypercholesterolemia, is caused by mutations around codon 3500 of the apo B gene. We have compared the ability of three molecular-scanning techniques, heteroduplex analysis, single-strand conformation polymorphism (SSCP) analysis, and denaturing gradient gel electrophoresis (DGGE), to detect these mutations in a cohort of 432 hypercholesterolemic individuals. Heteroduplex analysis and DGGE detected 11 individuals with apo B mutations, 9 of whom were heterozygous for apo B R3500Q and 2 who were heterozygous for apo B R3531C. Whereas DGGE was able to distinguish between these two mutations, heteroduplex analysis was technically simpler and gave a higher sample throughput. In contrast, SSCP analysis detected only 7 of the R3500Q and none of the R3531C heterozygotes and was the most complex of the three techniques. We believe heteroduplex analysis to be the method of choice for screening large numbers of samples for FDB.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299944

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Rapid detection of 3500Q and 3531 mutations and MspI polymorphism in exon 26 at the apolipoprotein B gene.

Authors:  S A Cavalli; M H Hirata; R D Hirata
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  Absence of Apo B R3500Q Mutation among Kelantanese Malays with Hyperlipidaemia.

Authors:  W M Kyi; M N Isa; F A Rashid; J M Osman; M A Mansur
Journal:  Malays J Med Sci       Date:  2000-01

Review 3.  Molecular approaches in the diagnosis of primary immunodeficiency diseases.

Authors:  Maurizio Costabile; Alex Quach; Antonio Ferrante
Journal:  Hum Mutat       Date:  2006-12       Impact factor: 4.878

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.